Implementation of European standards of care for cystic fibrosis - Control and treatment of infection

Journal of Cystic Fibrosis

Volumn 8, Issue 3, 2009, Pages 211-217

  Elborn, J S ^a   Hodson, M ^b   Bertram, C ^c  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c London ^*  (United Kingdom)

Author keywords

Cystic fibrosis; European; Infection; Pseudomonas aeruginosa; Survey

Indexed keywords

ANTIBIOTIC AGENT; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; GENTAMICIN; TOBRAMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BURKHOLDERIA CEPACIA; CHILD; CYSTIC FIBROSIS; DISEASE EXACERBATION; EARLY INTERVENTION; EUROPE; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH SURVEY; HUMAN; INFECTION CONTROL; MAJOR CLINICAL STUDY; PATIENT CARE; PRACTICE GUIDELINE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; QUALITATIVE ANALYSIS; TREATMENT DURATION;

ADMINISTRATION, INHALATION; ADULT; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BURKHOLDERIA CEPACIA; BURKHOLDERIA INFECTIONS; CHILD; CHILD, PRESCHOOL; CIPROFLOXACIN; COLISTIN; CYSTIC FIBROSIS; EUROPE; GUIDELINE ADHERENCE; HUMANS; INFECTION CONTROL; PRACTICE GUIDELINES AS TOPIC; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; QUESTIONNAIRES; RESPIRATORY TRACT INFECTIONS; TOBRAMYCIN; YOUNG ADULT;

EID: 67349236628     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2009.03.001     Document Type: Article

References (30)

1. Fitzsimmons S.C. The changing epidemiology of cystic fibrosis. J Pediatr 122 (1993) 1-9
2. Kerem E., Conway S., Elborn S., and Heijerman H. Standards of care for patients with cystic fibrosis: a European consensus. J Cyst Fibros 4 (2005) 7-26
3. Ramsay B., Pepe M.S., Quan J.M., et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 340 (1999) 23-30
4. Gilligan P.H. Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev 4 (1991) 35-51
5. Denton M., and Wilcox M. Antimicrobial treatment of pulmonary colonization and infection by Pseudomonas aeruginosa in cystic fibrosis patients. J Antimicrob Chemother 40 (1997) 468-474
6. Harrison F. Microbial ecology of the cystic fibrosis lung. Microbiology 153 (2007) 917-923
7. Cystic Fibrosis Foundation Patient Registry. Annual data report 2006 (2006). http://www.cff.org/LivingWithCF/CareCenterNetwork/PatientRegistry/ www.cff.org/LivingWithCF/CareCenterNetwork/PatientRegistry/
8. Arkwright P.D., Pravica V., Geraghty P.J., et al. End-organ dysfunction in cystic fibrosis: Association with angiotensin I converting enzyme and cytokine gene polymorphisms. Am J Respr Crit Care 167 (2003) 384-389
9. Cystic Fibrosis Foundation Patient Registry. Annual data report 2004 (2004), Cystic Fibrosis Foundation, Bethesda
10. Cystic Fibrosis Trust Clinical Standards and Accreditation Group. Standards for the clinical care of children and adults with cystic fibrosis in the UK (2001), Cystic Fibrosis Trust, London
11. Schidlow D.V., Taussig L.M., and Knowles M.R. Cystic Fibrosis Foundation consensus conference report on pulmonary complications of cystic fibrosis. Pediatr Pulmonol 15 (1993) 187-198
12. Doring G., Conway S.P., Heijerman H.G., et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 16 (2000) 749-767
13. Elborn S. Implementation of European Standards of Care for cystic fibrosis - provisions of care [Journal and citation to be completed - companion survey manuscript in the same issue].
14. Smyth A., and Elborn J.S. Exacerbations in cystic fibrosis: 3 management. Thorax 63 (2008) 180-184
15. Emerson J., Rosenfield M., McNamara S., Ramsay B., and Gibson R.L. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 34 (2002) 91-100
16. Pamukcu A., Bush A., and Buchdal R. Effects of P. aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis. Pediatr Pulmonol 19 (1995) 10-15
17. Winnie G.B., and Cowan R.G. Respiratory tract colonization with Pseudomonas aeruginosa in cystic fibrosis: correlations between anti-Pseudomonas aeruginosa antibody levels and pulmonary function. Pediatr Pulmonol 10 (1991) 92-100
18. Van daele S.G., Franckx H., Verhelst R., et al. Epidemiology of Pseudomonas aeruginosa in a cystic fibrosis rehabilitation centre. Eur Respir J 25 (2005) 474-481
19. Brennan A.L., and Geddes D.M. Cystic fibrosis. Curr Opin Infect Dis 15 (2002) 175-182
20. Wood D.M., and Smyth A.R. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (review). Cochrane Libr 3 (2007) 1-19. http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004197/pdf_fs.html http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004197/pdf_fs.html
21. Nixon G.M., Armstrong D.S., Carzino R., et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 138 (2001) 699-704
22. Cystic Fibrosis Foundation. The Burkholderia cepacia Complex - Suggestions for Prevention and Infection Control. 2nd ed (2004). http://www.cftrust.org.uk/aboutcf/publications/consensusdoc/C_Burkholderia_cepacia_Sep_2004.pdf http://www.cftrust.org.uk/aboutcf/publications/consensusdoc/C_Burkholderia_cepacia_Sep_2004.pdf
23. Courtney J.M., Dunbar K.E., McDowell A., et al. Clinical outcome of Burkholderia cepacia complex infection in cystic fibrosis adults. J Cyst Fibros 3 (2004) 93-98
24. Govan J.R., Hughes J.E., and Vandamme P. Burkholderia cepacia: medical, taxonomic and ecological issues. J Med Microbiol 45 (1996) 395-407
25. Lebecque P., Leal T., Zylberberg K., Reychler G., Bossuyt X., and Godding V. Towards zero prevalence of chronic Pseudomonas aeruginosa infection in children with cystic fibrosis. J Cyst Fibros 5 (2006) 237-244
26. Conway S.P., Pond M.N., Watson A., Etherington C., Robey H.L., and Goldman M.H. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. Thorax 52 (1997) 987-993
27. Hodson M.E., Gallagher C.G., and Govan J.R.W. A randomized clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 20 (2002) 658-664
28. Jensen T., Pedersen S.S., Garne S., Heilmann C., Høiby N., and Koch C. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 19 (1987) 831-838
29. Moriarty T.F., McElnay J.C., Elborn J.S., and Tunney M.M. Sputum antibiotic concentrations: implications of cystic fibrosis lung infection. Pediatr Pulmonol 42 (2007) 1008-1017
30. Cystic Fibrosis Worldwide. Towards equal access to appropriate care for all CF patients in Europe (2006). http://www.cfww.org/cfe/cfe.awareness-day-equal-access.asp http://www.cfww.org/cfe/cfe.awareness-day-equal-access.asp